Abstract
Anaplastic thyroid carcinoma (ATC) is a rare aggressive malignancy characterized by a rapidly progressive clinical course nearly always culminating in the fatal outcome. Rare reports of successful treatment and anecdotal accounts of long-term survivors of ATC contribute to the therapeutic nihilism related to ATC, although promising new treatment approaches are emerging. ATC is a rare malignancy, accounting for only 1–2% of thyroid carcinomas. In the United States, the incidence of ATC is approximately 300 cases per year, and is similar to other developed countries (Kebebew et al. Cancer;103(7):1330–5, 2005; Ain. Thyroid ;8(8):715–26, 1998). Almost all of ATC occurs in individuals above 50 years of age, and most patients present in the seventh decade of life. Slight female to male predominance has been noted, in the 1.5–2 range (Kebebew et al. Cancer;103(7):1330–5, 2005; Ain. Thyroid;8(8):715–26, 1998). The incidence of ATC has been declining in the last 20 years, perhaps reflecting more accurate classification of thyroid neoplasms, higher detection rates, and more aggressive treatment of differentiated thyroid carcinoma (DTC), which is considered to be a precursor to ATC (Ain. Thyroid;8(8):715–26, 1998; Chiacchio et al. Endocrinol;33(4):341–57, 2008).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330–5.
Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 1998;8(8):715–26.
Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol. 2008;33(4):341–57.
Wreesmann VB, Singh B. Clinical impact of molecular analysis on thyroid cancer management. Surg Oncol Clin N Am. 2008;17(1):1–35.
Zitzelsberger H, Bauer V, Thomas G, Unger K. Molecular rearrangements in papillary thyroid carcinomas. Clin Chim Acta. 2009;411(5–6):301–8.
Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996;40(5):953–8.
Guarda LA, Peterson CE, Hall W, Baskin HJ. Anaplastic thyroid carcinoma: cytomorphology and clinical implications of fine-needle aspiration. Diagn Cytopathol. 1991;7(1):63–7.
Miettinen M, Franssila KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol. 2000;31(9):1139–45.
Tan RK, Finley 3 RK, Driscoll D, Bakamjian V, Hicks Jr WL, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995;17(1):41–7. discussion 47–8.
Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000;11(9):1083–9.
Bogsrud TV, Karantanis D, Nathan MA, et al. 18 F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid. 2008;18(7):713–9.
Lazar V, Bidart J-M, Caillou B, et al. Expression of the Na/I symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab. 1999;84:3228–34.
Ciampi R, Vivaldi A, Romei C, et al. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol. 2008;291:57–62. Epub 2008 May 14.
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001;25(5):617–22.
Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453–64. Epub 2006 Feb 15.
McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130(6):1028–34.
Cobin RH, Gharib H, Bergman DAL. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid cancer. Endocr Pract. 2001;7:203–20.
Sugino K, Ito K, Mimura T, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery. 2002;131:2458.
Venkatesh YSS, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid. A clinicopathological study of 121 cases. Cancer. 1990;66:321–30.
Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery. 1991;110:956–63.
Shaha AR. Airway management in anaplastic thyroid carcinoma. Laryngoscope. 2008;118(7):1195–8.
Levendag PC, De Porre PM, van Putten WL. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys. 1993;26:125–8.
Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 1992;18:83–8.
Kobayashi T, Asakawa H, Umeshita K, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck. 1996;18(1):36–41. Jan–Feb.
Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 1987;60:2372–5.
Tenvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86:1848–53.
Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 1987;10:303–10.
De Besi P, Busnardo B, Toso S, et al. Combined chemotherapy with bleomycin, adriamycin and platinum in advanced thyroid carcinoma. J Endocrinol Invest. 1991;14:475–80.
Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000;10(7):587–94.
Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma–treatment outcome in 75 patients. Radiother Oncol. 2009;92(1):100–4. Epub 2009 Mar 26.
De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1137–43.
Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 2007;14(2):719–29. Epub 2006 Nov 10.
Hogan T, Jing Jie Yu, Williams HJ, Altaha R, Liang Xiaobing, Qi HE. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract. 2009;15(2):111–7. Epub 2009 Mar 10.
Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs. 2009;18(2):189–97.
Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab. 2007;92(8):2902–9. Aug. Epub 2007.
Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19(3):233–40.
Kim S, Yazici YD, G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther. 2007;6(6):1785–92.
Nagaiah G, Fu P, Wasman K, et al. Phase II trial of sorafenib (bay 43–9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol. 2009;27:15s. suppl; abstr 6058.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Vaysburd, M. (2012). Anaplastic Thyroid Carcinoma. In: Braunstein, G. (eds) Thyroid Cancer. Endocrine Updates, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0875-8_10
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0875-8_10
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-0874-1
Online ISBN: 978-1-4614-0875-8
eBook Packages: MedicineMedicine (R0)